Evidence map›Paper›PMID 37260355›Full record

ArticleInternational journal of cancer2023

Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c-Met to up-regulate angiogenesis and lung adenocarcinoma growth.

Pinelopi Kastana, Despoina Ntenekou, Eleni Mourkogianni, Michaela-Karina Enake, Athanasios Xanthopoulos, Effrosyni Choleva, Antonia Marazioti, Sophia Nikou, Racheal G Akwii, Eleni Papadaki and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Pinelopi KastanaLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Despoina NtenekouLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Eleni MourkogianniLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Michaela-Karina EnakeLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Athanasios XanthopoulosLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Effrosyni CholevaLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Antonia MaraziotiLaboratory of Molecular Respiratory Carcinogenesis, Faculty of Medicine, Department of Physiology, University of Patras, Patras, Greece.
Sophia NikouDepartment of Anatomy, Faculty of Medicine, University of Patras, Patras, Greece.
Racheal G AkwiiDepartment of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Eleni PapadakiDepartment of Anatomy, Faculty of Medicine, University of Patras, Patras, Greece.
Esther GramageDepartamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
Gonzalo HerradónDepartamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
Georgios T StathopoulosLaboratory of Molecular Respiratory Carcinogenesis, Faculty of Medicine, Department of Physiology, University of Patras, Patras, Greece.
Constantinos M MikelisLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.
Evangelia PapadimitriouLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece.ORCID 0000-0001-6429-4325
University of Patras · GRTexas Tech University · USUniversidad San Pablo CEU · ES

Funding

Novel Class of Chemotherapeutic Agents for Treatment of Metastatic Triple-negative Breast CancerR15CA231339 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI GERMAN, NADEZHDA A, MIKELIS, CONSTANTINOS MARIOS · 2018 to 2018
$459k
NCI NIH HHS R15 CA231339NIH HHS R15CA231339
6 · The paper itself

Abstract

Protein tyrosine phosphatase receptor zeta 1 (PTPRZ1) is a transmembrane tyrosine phosphatase (TP) expressed in endothelial cells and required for stimulation of cell migration by vascular endothelial growth factor A

Indexed as

Adenocarcinoma of LungReceptor-Like Protein Tyrosine Phosphatases, Class 5AnimalsEndothelial CellsMiceProtein Tyrosine PhosphatasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metTyrosineVascular Endothelial Growth Factor AProtein Tyrosine PhosphatasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metPtprz1 protein, mouseReceptor-Like Protein Tyrosine Phosphatases, Class 5TyrosineVascular Endothelial Growth Factor Aendothelial cellshepatocyte growth factor receptorintegrinpleiotrophinVEGFA

Identifiers

PMID37260355
PMCPMC10524925
OpenAlexW4378953725

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.